NasdaqGS - Delayed Quote USD

Cytek Biosciences, Inc. (CTKB)

Compare
5.34 +0.02 (+0.38%)
At close: October 15 at 4:00 PM EDT
Loading Chart for CTKB
DELL
  • Previous Close 5.32
  • Open 5.29
  • Bid 5.33 x 200
  • Ask 5.36 x 200
  • Day's Range 5.25 - 5.47
  • 52 Week Range 3.80 - 9.87
  • Volume 649,924
  • Avg. Volume 619,925
  • Market Cap (intraday) 702.242M
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) -0.14
  • Earnings Date Aug 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.10

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

cytekbio.com

645

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CTKB

View More

Performance Overview: CTKB

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CTKB
41.45%
S&P 500
21.92%

1-Year Return

CTKB
6.37%
S&P 500
34.37%

3-Year Return

CTKB
76.72%
S&P 500
31.03%

5-Year Return

CTKB
73.43%
S&P 500
31.81%

Compare To: CTKB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CTKB

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    702.24M

  • Enterprise Value

    438.80M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.59

  • Price/Book (mrq)

    1.80

  • Enterprise Value/Revenue

    2.22

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.88%

  • Return on Assets (ttm)

    -3.01%

  • Return on Equity (ttm)

    -4.32%

  • Revenue (ttm)

    197.71M

  • Net Income Avi to Common (ttm)

    -17.56M

  • Diluted EPS (ttm)

    -0.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    277.21M

  • Total Debt/Equity (mrq)

    3.54%

  • Levered Free Cash Flow (ttm)

    30.25M

Research Analysis: CTKB

View More

Company Insights: CTKB

Research Reports: CTKB

View More

People Also Watch